Protalix (PLX) Form 3: Sr. VP/CFO Discloses 597,990-Share Option

Rhea-AI Filing Summary

Protalix BioTherapeutics (PLX) Form 3: Gilad Mamlok, Sr. VP and CFO, filed an initial Form 3 reporting derivative securities on 08/24/2025. The filing shows a stock option exercisable beginning 07/20/2035 covering 597,990 shares of common stock at an exercise price of $1.45 per share. The option is held directly and vests in 12 equal quarterly installments commencing on the grant date, with accelerated vesting provisions upon a corporate transaction or change in control under the company’s amended 2006 Stock Incentive Plan. The form is signed by Gilad Mamlok on 08/25/2025.

Positive

• Insider alignment: CFO holds a sizeable equity-linked award of 597,990 options, aligning management and shareholder interests
• Clear vesting and acceleration: Options vest in 12 equal quarterly installments and include accelerated vesting on a corporate transaction or change in control

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine initial Form 3 disclosing a large stock option grant to the CFO; no cash flow or revenue impact disclosed.

This Form 3 documents an insider disclosure rather than an operational result. The filing reports a single stock option for 597,990 shares at a $1.45 exercise price with multi-year exercisability and quarterly vesting. For investors, this is primarily governance and compensation information indicating executive equity alignment; it does not provide earnings, cash, debt, or transaction details.

Corporate Governance Expert

TL;DR: Standard initial beneficial-ownership filing for an officer with customary vesting and change-in-control acceleration.

The disclosure identifies the reporting person as Sr. VP and CFO and describes vesting mechanics and accelerated vesting on corporate transactions per the company’s incentive plan. The filing is procedural compliance with Section 16 reporting requirements and contains no atypical restrictive covenants, waivers, or amendments to the plan text beyond referencing the plan.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Mamlok Gilad

(Last) (First) (Middle)

CO PROTALIX BIOTHERAPEUTICS, INC.

(Street)

CARMIEL L3 2161401

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/24/2025

3. Issuer Name and Ticker or Trading Symbol
Protalix BioTherapeutics, Inc. [ PLX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP and CFO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	07/20/2035	Common Stock	597,990	$1.45	D

Explanation of Responses:

1. The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

	/s/ Gilad Mamlok	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Gilad Mamlok report on Form 3 for PLX?

He reported a stock option for 597,990 shares of common stock with an exercise price of $1.45, filed as an initial Form 3.

When is the option exercisable and what is the exercise price?

The option is listed with a date exercisable of 07/20/2035 and an exercise price of $1.45 per share.

What is the vesting schedule for the reported options?

Vesting occurs in 12 equal quarterly installments commencing on the grant date; the options have accelerated vesting upon a corporate transaction or change in control.

What is Gilad Mamlok’s role at Protalix BioTherapeutics (PLX)?

The filing identifies him as Sr. VP and CFO and indicates he is a reporting insider.

On what dates were the event and the Form 3 signed?

The event date is 08/24/2025 and the Form 3 is signed by Gilad Mamlok on 08/25/2025.